RecruitingNCT04543461
American Lung Association (ALA) Lung Health Cohort
The American Lung Association (ALA) Lung Health Cohort
Sponsor
Johns Hopkins University
Enrollment
4,000 participants
Start Date
Oct 29, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Eligibility
Min Age: 25 YearsMax Age: 35 Years
Inclusion Criteria2
- - Age 25-35 years at the time of the baseline examination 2- Able to read and understand English or Spanish 3 -Has a social security number 4- Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination. Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.
- - Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant
Exclusion Criteria15
- Severe asthma, which is defined as any of the following:
- Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = >250 fluticasone, propionate =100 fluticasone furoate, >200 beclomethasone, >400 budesonide, >220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS.
- OR
- 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
- One asthma hospitalization in the past 12 months
- History of any chronic lung disease other than asthma including but not limited to COPD, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
- Current pregnancy
- History of cancer other than non-melanoma skin cancer
- Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)
- Inability to comply with study procedures, including
- Inability or unwillingness to provide informed consent
- Inability to perform study measurements
- Inability to be contacted by phone (via calls and/or text messaging) or email
- Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).
- Institutionalization
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(37)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04543461
Related Trials
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
NCT0643163330 locations
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT073331831 location
Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients
NCT067287091 location
Respiratory Muscles and Work of Breathing in Children
NCT050512541 location
Comparison of Two Strategies of One-lung Ventilation in Patients Undergoing Carcinological Lung Resection Surgery.
NCT055253121 location